# Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia

> **NCT00615784** · PHASE2 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 24 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Bexarotene

## Key facts

- **NCT ID:** NCT00615784
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05-25
- **Primary completion:** 2013-10-01
- **Final completion:** 2013-11-08
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Study terminated. Eisai's Targretin acquired by another pharmaceutical company.
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00615784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00615784, "Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00615784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*